Search clinical trials for: pembrolizumab (KEYTRUDA)

Total 2351 results

Crozer-Keystone Health System
Saint Peters University Hospital; Community Medical Center, Toms River, NJ

Completed

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect (I-SABR)

Non Small Cell Lung Cancer | Metastatic Nonsmall Cell Lung Cancer

United States
Yonsei University

Not yet recruiting

Phase II Study of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) With Previously Treated Advanced Gastric Cancer

Gastric and Gastroesophageal Junction Adenocarcinoma
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Active, not recruiting

Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP)

Carcinoma of Unknown Primary

Canada
Lynn Feun, MD
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...

Recruiting

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)

Invasive Bladder Cancer

United Kingdom
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Tumor

China
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom

Terminated

PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (PEACH)

Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma

United Kingdom
Amgen

Not yet recruiting

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) (Eucalyptus)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Evopoint Biosciences Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Carcinoma | Cervical Cancer | Prostate Cancer | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Other Solid Tumors

China
Sandoz

Not yet recruiting

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Melanoma
Lyvgen Biopharma Holdings Limited
Merck Sharp & Dohme LLC

Recruiting

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Cancer

United States
BerGenBio ASA
Merck Sharp & Dohme LLC

Completed

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Lung Cancer Metastatic | Adenocarcinoma of Lung | NSCLC Stage IV

United States, Spain, United Kingdom, Norway
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway
Universitaire Ziekenhuizen KU Leuven

Completed

Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Neoplasm

Belgium
Saad A Khan
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Anaplastic Thyroid Cancer

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...

Completed

Pembrolizumab and Palliative Radiotherapy in Lung (PEAR)

Thoracic Tumours

United Kingdom
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
Henry Ford Health System

Recruiting

HFHS-1801-A Pilot Study of Immunotherapy as Consolidation Therapy for Patients With Recurrent Head and Neck Cancer

Head and Neck Neoplasms

United States
Ashwin Somasundaram
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Active, not recruiting

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Hepatocellular Carcinoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64)

Melanoma

United States
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Anti-PD1 Antibody

China
Sorrento Therapeutics, Inc.

Recruiting

Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

Mycosis Fungoides

United States
Oncolytics Biotech

Completed

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Genexine, Inc.
Merck Sharp & Dohme LLC

Completed

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Cervical Cancer

Korea, Republic of
Tianjin Chest Hospital

Recruiting

Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD

NSCLC With COPD

China
RAPT Therapeutics, Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Advanced Cancer

Hong Kong, United States, Australia, Korea, Republic of, Taiwan, Thailand
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Active, not recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Bladder Urothelial Cancer | Endocervical...

United States
Adagene Inc
Merck Sharp & Dohme LLC

Completed

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

United States
Assuta Hospital Systems

Unknown

Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women

Pregnancy Complications, Hematologic

Israel
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Squamous Cell Carcinoma of Head and Neck

Spain, France, United States, Germany, Italy, Poland, United Kingdom
Turnstone Biologics, Corp.

Completed

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer

Canada
Bayer
Merck Sharp & Dohme LLC

Completed

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Advanced Solid Tumors

United States, Spain, Germany, Switzerland, United Kingdom
Mark Pomerantz, MD
Merck Sharp & Dohme LLC; Rainier Therapeutics

Terminated

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Bladder Cancer

United States
CHA University
Merck Sharp & Dohme LLC

Not yet recruiting

Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP) (CR-GTP)

Gestational Trophoblastic Neoplasia

Korea, Republic of
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
Adagene Inc
Merck Sharp & Dohme LLC

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

Korea, Republic of, United States
Qurient Co., Ltd.
Merck Sharp & Dohme LLC

Recruiting

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Metastatic Cancer | Advanced Cancer

United States, Korea, Republic of
Biocad

Active, not recruiting

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Melanoma (Skin)

Russian Federation
Providence Health & Services
Galectin Therapeutics Inc.

Completed

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients

Melanoma | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

ESCC | Adjuvant Treatment | Lymph Node Positive | Pembrolizumab

China
ProgenaBiome

Completed

A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma

Mesothelioma

United States
invoX Pharma Limited
Merck Sharp & Dohme LLC

Recruiting

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Metastatic Cancer | Advanced Cancer

Spain, United States
Aethlon Medical Inc.

Terminated

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Erasmus Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab (RESPONDER)

Biomarkers | Transitional Cell Carcinoma of the Bladder

Netherlands
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
ImmunOs Therapeutics AG
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

Solid Tumor, Adult

Australia

Search clinical trials for: pembrolizumab (KEYTRUDA)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations